Sigilon Therapeutics, Inc
Sigilon’s super-biocompatible Afibromer™ technology allows us to create a new class of implantable cell-based Living Therapeutics™ that will “fly under the radar” of the immune system to avoid detection and rejection. Many patients can benefit from cell-based therapeutics, but fibrosis has presented a barrier to the success of encapsulated cell-based approaches. Living Therapeutics provide a unique, controllable and dose-adjustable approach to delivering protein therapeutics that do not trigger fibrosis.
Sigilon’s Living Therapeutics act as cell factories and allow us to program and control dynamic protein delivery (e.g. enzymes, factors and antibodies). This allows for the long-term treatment of debilitating diseases without the need for immune suppression that is traditionally associated with allogeneic cell therapies.
Living Therapeutics can also be designed to provide multiple proteins simultaneously. Our approach also allows us to develop long term programmable implants that can be upgraded when required or removed if desirable to provide control.
